Shenoy Lab

My academic focus is on the development of safer less toxic methods of hematopoietic stem cell transplantation in children. Toward this, I am investigating reduced intensity transplantation for children with hemoglobinopathy (sickle cell disease and thalassemia) using the best available related or alternate donors.  

Based on a preliminary multi-center trial that was previously completed, a national trial of unrelated donor marrow transplantation for severe sickle cell disease is ongoing under the Bone Marrow Transplant Clinical Trials Network (BMT CTN) and is called the SCURT Trial (BMT CTN 0601). 

Another trial for thalassemia has just been completed under the Thalassemia Clinical research Network (TCRN) and Pediatric Blood and Marrow transplant Consortium (PBMTC) – called the URTH trial. We are now exploring reduced intensity transplantation for non-malignant disorders including hemoglobinopathy using minimally mismatched marrow or cord blood donors in a separate study (01-0923).

Principal investigator

Shalini Shenoy, MD, MBBS

Professor of Pediatrics, Hematology & Oncology
Director, Stem Cell Transplant & Cellular Therapy Program

• Phone: 314-454-6018

Recent publications

• Hyperthyroidism following transplantation and SARS-CoV-2 exposure
  December 1, 2023
  Hyperthyroidism following transplantation and SARS-CoV-2 exposureElnaggar, M. & Shenoy, S., Dec 2023, In: Pediatric Blood and Cancer. 70, 12, e30713.Research output: Contribution to journal › Letter › peer-review
• Mixed donor chimerism following stem cell transplantation for sickle cell disease
  November 1, 2023
  Mixed donor chimerism following stem cell transplantation for sickle cell diseaseShah, N. C., Rangarajan, H. G., Ngwube, A. & Shenoy, S., Nov 1 2023, In: Current opinion in hematology. 30, 6, p. 187-193 7 p.Research output: Contribution to journal › Review article › peer-review
• Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation
  September 1, 2023
  Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantationKitko, C. L., Bollard, C. M., Cairo, M. S., Chewning, J., Fry, T. J., Pulsipher, M. A., Shenoy, S., Wall, D. A. & Levine, J. E., Sep 2023, In: Pediatric Blood and Cancer. 70, S6, e30577.Research output: Contribution to journal › Article › peer-review
• Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events
  August 24, 2023
  Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse eventsTakahashi, T., Al-Kofahi, M., Jaber, M., Bratrude, B., Betz, K., Suessmuth, Y., Yu, A., Neuberg, D. S., Choi, S. W., Davis, J., Duncan, C., Giller, R., Grimley, M., Harris, A. C., Jacobsohn, D., Lalefar, N., Farhadfar, N., Pulsipher, M. A., Shenoy, S., Petrovic, A., & 8 othersSchultz, K. R., Yanik, G. A., Blazar, B. R., Horan, J. T., Watkins, B., Langston, A., Qayed, M. & Kean, L. S., Aug 24 2023, In: Blood. 142, 8, p. 700-710 11 p.Research output: Contribution to journal › Article › peer-review
• Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium
  July 8, 2023
  Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment ConsortiumThakar, M. S., Logan, B. R., Puck, J. M., Dunn, E. A., Buckley, R. H., Cowan, M. J., O'Reilly, R. J., Kapoor, N., Satter, L. F., Pai, S. Y., Heimall, J., Chandra, S., Ebens, C. L., Chellapandian, D., Williams, O., Burroughs, L. M., Saldana, B. D., Rayes, A., Madden, L. M., Chandrakasan, S., & 45 othersBednarski, J. J., DeSantes, K. B., Cuvelier, G. D. E., Teira, P., Gillio, A. P., Eissa, H., Knutsen, A. […]